Page last updated: 2024-10-23

aspirin and Left Ventricular Dysfunction

aspirin has been researched along with Left Ventricular Dysfunction in 70 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin."9.20Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015)
" In the present retrospective analysis of the randomized, double-blind, parallel-group, SMILE-4 study we compared the efficacy of zofenopril 60 mg and acetylsalicylic acid (ASA) 100 mg versus ramipril 10 mg and ASA in patients with AMI complicated by left ventricular dysfunction, classified according to a history of hypertension."9.17Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. ( Ambrosio, G; Ambrosioni, E; Bacchelli, S; Borghi, C; Cicero, AF; Esposti, DD; Omboni, S; Vinereanu, D; Zava, D, 2013)
"This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction <45%) following acute myocardial infarction (AMI)."9.16Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Vinereanu, D, 2012)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."9.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."8.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
"The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid."7.85Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2017)
"In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction."7.83Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016)
"An adverse interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors is suspected in patients with heart failure, but the effect of combined therapy with these agents on hospital readmission rates is unknown."7.71Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. ( Harjai, KJ; Newman, J; Nunez, E; Turgut, T, 2001)
"Pretreatment with aspirin did not change the vasodilator responses in any group."6.69Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. ( Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Montagne, O; Sediame, S, 1999)
"Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction."5.20Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015)
"We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin."5.20Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015)
" In the present retrospective analysis of the randomized, double-blind, parallel-group, SMILE-4 study we compared the efficacy of zofenopril 60 mg and acetylsalicylic acid (ASA) 100 mg versus ramipril 10 mg and ASA in patients with AMI complicated by left ventricular dysfunction, classified according to a history of hypertension."5.17Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. ( Ambrosio, G; Ambrosioni, E; Bacchelli, S; Borghi, C; Cicero, AF; Esposti, DD; Omboni, S; Vinereanu, D; Zava, D, 2013)
"This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction <45%) following acute myocardial infarction (AMI)."5.16Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Vinereanu, D, 2012)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."5.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."4.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
"We used the Peto-Yusuf method to undertake a systematic overview of data for 22060 patients from six long-term randomised trials of ACE inhibitors to assess whether aspirin altered the effects of ACE inhibitor therapy on major clinical outcomes (composite of death, myocardial infarction, stroke, hospital admission for congestive heart failure, or revascularisation)."4.81Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. ( Collins, R; Hall, A; Kober, L; Latini, R; Pfeffer, M; Pogue, J; Teo, KK; Torp-Pedersen, C; Yusuf, S, 2002)
" New pharmaceutical compounds such as renin inhibitors, angiotensin II receptor antagonists and aldosterone antagonists are bringing new insights not only into the importance of different components of the renin-angiotensin-aldosterone system in heart failure but also into the mode of action of angiotensin-converting enzyme inhibitors."4.79Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research. ( Cleland, JG; Morgan, K, 1996)
"The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid."3.85Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2017)
"In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction."3.83Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016)
" Anticoagulants are effective in stroke prevention in atrial fibrillation with aspirin being a less effective alternative."3.72Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening? ( Buchalter, M; Burr, ML; Ho, SF; O'Mahony, MS; Steward, JA, 2004)
" These results together with other previously published circumstantial evidence urge for a prospective, controlled and randomised trial specifically designed to evaluate optimal oral anticoagulants and aspirin in patients with congestive heart failure."3.71Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). ( Admant, P; Aliot, E; Alla, F; Allam, S; Baille, N; Bellanger, P; Breton, Ch; Briançon, S; D'Hôtel, R; Dambrine, P; Dodet, JF; Ducimetière, P; Echemann, M; Fagnani, F; Graille, M; Guize, L; Juillière, Y; Kessler, M; KhalifE, K; Mertès, PM; Neimann, JL; Rebeix, G; Saulnier, JP; Thisse, JY; Trutt, B; Vidal, P; Villemot, JP; Virion, JM; Vuillemin, MCh; Zannad, F, 2002)
"An adverse interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors is suspected in patients with heart failure, but the effect of combined therapy with these agents on hospital readmission rates is unknown."3.71Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. ( Harjai, KJ; Newman, J; Nunez, E; Turgut, T, 2001)
"The equivalent of the clinically used low (= antiplatelet)-dose aspirin, inhibited collagen deposition in the non-infarcted myocardium in rats with myocardial infarction."3.70Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats. ( Kalkman, EA; Saxena, PR; Schoemaker, RG, 1998)
"Pretreatment with aspirin did not change the vasodilator responses in any group."2.69Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. ( Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Montagne, O; Sediame, S, 1999)
" However, we know that ejection fraction and symptom class do not always match and that the regulation of warfarin dosing is more difficult in worsening heart failure."2.41Anticoagulation and heart failure. ( Graham, SP, 2001)
"Intermittent left bundle branch block is a conduction disturbance that has been described to be associated with myocardial bridges and cardiac memory."1.51Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report. ( Ibarrola, M, 2019)
"Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs."1.37Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure. ( Abegunewardene, N; Gori, T; Horstick, G; Kreitner, KF; Lehr, HA; Münzel, T; Schmidt, KH; Schreiber, LM; Vosseler, M, 2011)
"None experienced strokes or transient ischemic attacks."1.35Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. ( Dia, M; Gallagher, C; Silver, MA; Slaughter, MS; Sobieski, MA, 2008)
"Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking."1.32Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004)
"Approximately 50% of patients recovering from acute myocardial infarction have significant left ventricular systolic dysfunction and could benefit considerably from the long-term administration of angiotensin-converting enzyme inhibitors."1.30ACE inhibitors in acute myocardial infarction. ( McMurray, JJ; Murdoch, DR, 1998)
"Left ventricular dysfunction was attributed to idiopathic dilated cardiomyopathy in 18 and coronary artery disease in 19 patients."1.30Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. ( Atar, D; Gurbel, PA; Lowry, DR; Murugesan, SR; O'Connor, CM; Pothula, A; Serebruany, VL, 1999)
"The essential goal of medical treatment following myocardial infarction with left ventricular dysfunction must be the prevention of secondary cardiac failure."1.29[What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?]. ( Caviezel, B; Cohen-Solal, A; Gourgon, R; Himbert, D; Laperche, T, 1994)

Research

Studies (70)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (14.29)18.2507
2000's30 (42.86)29.6817
2010's26 (37.14)24.3611
2020's4 (5.71)2.80

Authors

AuthorsStudies
Berg, J1
Jablonowski, R1
Mohammad, M1
Solem, K1
Borgquist, R1
Ostenfeld, E1
Arheden, H1
Carlsson, M1
Merkler, AE1
Pearce, LA2
Kasner, SE1
Shoamanesh, A1
Birnbaum, LA1
Kamel, H1
Sheth, KN1
Sharma, R1
Valentini, G1
Huscher, D1
Riccardi, A1
Fasano, S1
Irace, R1
Messiniti, V1
Matucci-Cerinic, M1
Guiducci, S1
Distler, O1
Maurer, B1
Avouac, J1
Tarner, IH1
Frerix, M1
Riemekasten, G1
Siegert, E1
Czirják, L1
Lóránd, V1
Denton, CP1
Nihtyanova, S1
Walker, UA1
Jaeger, VK1
Del Galdo, F1
Abignano, G1
Ananieva, LP1
Gherghe, AM1
Mihai, C1
Henes, JC1
Schmeiser, T1
Vacca, A1
Moiseev, S1
Foeldvari, I1
Gabrielli, A1
Krummel-Lorenz, B1
Rednic, S1
Allanore, Y1
Müeller-Ladner, U1
Cherqaoui, B1
Koné-Paut, I1
Yager, H1
Bourgeois, FL1
Piram, M1
Kinter, CW1
Saxon, GE1
Ahmad, M2
Berhane, H1
Gensler, L1
Khosroshahi, A1
Hage, A1
Jacques, F1
Chetaille, P1
Bourdages, M1
Cloutier, K1
Perron, J1
Houde, C1
Ibarrola, M1
Lanzillo, C1
Di Roma, M1
Sciahbasi, A1
Minati, M1
Maresca, L1
Pendenza, G1
Romagnoli, E1
Summaria, F1
Patrizi, R1
Di Luozzo, M1
Preziosi, P1
Lioy, E1
Romeo, F1
Chen, K1
Williams, S1
Chan, AK1
Mondal, TK1
Borghi, C4
Ambrosioni, E4
Omboni, S3
Cicero, AF1
Bacchelli, S1
Esposti, DD1
Vinereanu, D4
Ambrosio, G5
Zava, D1
Blancas Gómez-Casero, R1
Quintana Díaz, M1
Chana García, M1
Martín Parra, C1
López Matamala, B1
Estébanez Montiel, B1
Ballesteros Ortega, D1
Martínez González, O1
Vigil Escribano, D1
Prieto Valderrey, F1
Marina Martínez, L1
Castro Gallego, O1
Adatya, S1
Adataya, S1
Masri, C1
John, R1
Eckman, P1
Prom, R1
Usedom, JE1
Dull, RB1
Weisel, RD1
Nussmeier, N1
Newman, MF1
Pearl, RG1
Wechsler, AS1
Pitt, B2
Clare, RM1
Pieper, KS1
Mongero, L1
Reece, TL1
Yau, TM1
Fremes, S1
Menasché, P1
Lira, A1
Harrington, RA1
Ferguson, TB1
Sandhu, RK1
Hohnloser, SH1
Pfeffer, MA1
Yuan, F1
Hart, RG3
Yusuf, S2
Connolly, SJ1
McAlister, FA2
Healey, JS1
Ye, S1
Cheng, B1
Lip, GY4
Buchsbaum, R1
Sacco, RL1
Levin, B1
Di Tullio, MR1
Qian, M1
Mann, DL1
Pullicino, PM1
Freudenberger, RS1
Teerlink, JR1
Mohr, JP1
Graham, S1
Labovitz, AJ1
Estol, CJ1
Lok, DJ1
Ponikowski, P1
Anker, SD2
Thompson, JL1
Homma, S2
Shyamali, NL1
Ranawaka, H1
Novo, S3
Slaughter, MS1
Sobieski, MA1
Gallagher, C1
Dia, M1
Silver, MA1
Nakashima, K1
Kirsch, ME1
Vermes, E1
Rosanval, O1
Loisance, D1
Schwalm, JD1
Salehian, O1
Eikelboom, JW1
Natarajan, MK1
Motwani, M1
Arya, S1
MacDonald, JE1
Gale, CP1
Metcalfe, E1
West, RM1
Das, R1
Kilcullen, N1
Morrell, C1
Crook, R1
Batin, PD1
Hall, AS1
Barth, JH1
Lemesle, G1
Delhaye, C1
Abegunewardene, N1
Schmidt, KH1
Vosseler, M1
Kreitner, KF1
Schreiber, LM1
Lehr, HA1
Gori, T1
Münzel, T1
Horstick, G1
El-Menyar, A1
AlHabib, KF1
Al-Motarreb, A1
Hersi, A1
Al Faleh, H1
Asaad, N1
Al Saif, S1
Almahmeed, W1
Sulaiman, K1
Amin, H1
Al-Lawati, J1
Alsheikh-Ali, AA1
AlQahtani, A1
Al-Sagheer, NQ1
Singh, R1
Al Suwaidi, J1
Oliveira, LH1
Mallmann, FB1
Botelho, FN1
Paul, LC1
Gianotto, M1
Abt, Rde B1
Silva, NJ1
Luize, CM1
Nogueira, FL1
Carvalho, RS1
Paola, AA1
Cirenza, C1
Swiatkiewicz, I1
Kozinski, M1
Magielski, P1
Gierach, J1
Fabiszak, T1
Kubica, A1
Sukiennik, A1
Navarese, EP1
Odrowaz-Sypniewska, G1
Kubica, J1
Cevik, C1
Shah, N1
Wilson, JM1
Stainback, RF1
Piotrponikowski, P1
Andreotti, F1
Filippatos, G1
Morais, J1
Pullicino, P1
Rasmussen, LH1
Marín, F1
Lane, DA1
Teo, KK1
Pfeffer, M1
Torp-Pedersen, C1
Kober, L1
Hall, A1
Pogue, J1
Latini, R2
Collins, R1
Echemann, M1
Alla, F1
Briançon, S1
Juillière, Y1
Virion, JM1
Mertès, PM1
Villemot, JP1
Zannad, F1
Aliot, E1
Breton, Ch1
KhalifE, K1
Neimann, JL1
Allam, S1
Admant, P1
Baille, N1
Bellanger, P1
D'Hôtel, R1
Dambrine, P1
Dodet, JF1
Graille, M1
Kessler, M1
Rebeix, G1
Saulnier, JP1
Thisse, JY1
Trutt, B1
Vidal, P1
Vuillemin, MCh1
Ducimetière, P1
Fagnani, F1
Guize, L1
Tereshchenko, SN1
Aleksandriia, LG1
Moiseev, VS1
Stöllberger, C1
Chnupa, P1
Abzieher, C1
Länger, T1
Finsterer, J1
Klem, I1
Hartl, E1
Wehinger, C1
Schneider, B1
Wienbergen, H1
Gitt, AK1
Schiele, R1
Juenger, C1
Heer, T1
Vogel, C1
Gottwik, M1
Senges, J1
Ruel, M1
Masters, RG1
Rubens, FD1
Bédard, PJ1
Pipe, AL1
Goldstein, WG1
Hendry, PJ1
Mesana, TG1
Ho, SF1
O'Mahony, MS1
Steward, JA1
Burr, ML1
Buchalter, M1
Gage, BF1
van Walraven, C1
Pearce, L1
Koudstaal, PJ1
Boode, BS1
Petersen, P1
Ezekowitz, J1
Humphries, KH1
Norris, CM1
Tonelli, M1
Ghali, WA1
Knudtson, ML1
Higashikuni, Y1
Sata, M1
Nagai, R1
Chin, BS1
Conway, DS1
Graham, JJ1
Timmis, A1
Cooper, J1
Ramdany, S1
Deaner, A1
Ranjadayalan, K1
Knight, C1
Granger, CB1
Steg, PG1
Peterson, E1
López-Sendón, J1
Van de Werf, F1
Kline-Rogers, E1
Allegrone, J1
Dabbous, OH1
Klein, W1
Fox, KA1
Eagle, KA1
Feringa, HH1
Bax, JJ1
Schouten, O1
Poldermans, D1
Chih, S1
McKeown, B1
Ferrier, N1
Bitar, G1
Marcaggi, X1
Amat, G1
Fu, Y1
Wang, Z1
Chen, WL1
Moore, PK1
Zhu, YZ1
Jha, AK1
Orav, EJ1
Li, Z1
Epstein, AM1
Cohen-Solal, A1
Himbert, D1
Caviezel, B1
Laperche, T1
Gourgon, R1
Elikowski, W1
Psuja, P1
Lewandowski, K1
Przybył, M1
Wendland, M1
Wróblewski, D1
Jazienicki, B1
Przybył, L1
Zawilska, K1
Cleland, JG1
Morgan, K1
Schoemaker, RG2
Saxena, PR2
Kalkman, EA2
Barron, HV1
Michaels, AD1
Maynard, C1
Every, NR1
Murdoch, DR1
McMurray, JJ1
Ghali, JK1
Maggioni, AP1
Benacerraf, S1
Carville, C1
Adnot, S1
Montagne, O1
Sediame, S1
Belhassen, L1
Dubois-Randé, JL1
Krumholz, HM1
Baker, DW1
Ashton, CM1
Dunbar, SB1
Friesinger, GC1
Havranek, EP1
Hlatky, MA1
Konstam, M1
Ordin, DL1
Pina, IL1
Spertus, JA1
Aronow, WS1
Ahn, C1
Kronzon, I1
Gutstein, H1
Van Kerckhoven, R1
Lancellotti, P1
Piérard, LA1
Serebruany, VL1
Murugesan, SR1
Pothula, A1
Atar, D1
Lowry, DR1
O'Connor, CM1
Gurbel, PA1
Peterson, JG1
Topol, EJ1
Sapp, SK1
Young, JB1
Lincoff, AM1
Lauer, MS1
Graham, SP1
Harjai, KJ1
Nunez, E1
Turgut, T1
Newman, J1
Edmunds, E1
Beevers, DG1
Bratzler, DW1
Oehlert, WH1
Walkingstick, K1
Murray, CK1
Shook, C1
Maranian, AM1
Steinhubl, SR1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909]Phase 37,213 participants (Actual)Interventional2014-12-23Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed)
The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction [NCT00872001]Phase 33,080 participants (Actual)Interventional2009-04-30Terminated
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205]Phase 290 participants (Actual)Interventional2017-11-07Completed
Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study[NCT01111071]316,648 participants (Actual)Observational2010-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Incidence Rate of a Major Bleeding Event According to the International Society on Thrombosis and Haemostasis (ISTH) Criteria (Adjudicated)

Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.82
Acetylsalicylic Acid 100 mg OD0.67

Incidence Rate of All-Cause Mortality

All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.88
Acetylsalicylic Acid 100 mg OD1.50

Incidence Rate of Any of the Following: Cardiovascular Death, Recurrent Stroke, Systemic Embolism and Myocardial Infarction

Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD6.20
Acetylsalicylic Acid 100 mg OD5.85

Incidence Rate of Clinically Relevant Non-Major Bleeding Events

Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD3.52
Acetylsalicylic Acid 100 mg OD2.32

Incidence Rate of Intracranial Hemorrhage

Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD0.70
Acetylsalicylic Acid 100 mg OD0.35

Incidence Rate of Life-Threatening Bleeding Events

Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.02
Acetylsalicylic Acid 100 mg OD0.43

Incidence Rate of the Composite Efficacy Outcome (Adjudicated)

Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD5.14
Acetylsalicylic Acid 100 mg OD4.78

Incidence Rate of the Following: Stroke, Ischemic Stroke, Disabling Stroke, Cardiovascular (CV) Death, Myocardial Infarction

"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

,
Interventionevent/100 participant-years (Number)
StrokeIschemic strokeDisabling strokeCV death(includes death due to hemorrhage)Myocardial infarction
Acetylsalicylic Acid 100 mg OD4.714.560.840.660.67
Rivaroxaban 15 mg OD5.114.711.200.990.49

Incidence of All-cause Death, Non-fatal Stroke, and Need for Mechanical Support for Severe Left Ventricular Dysfunction (SLVD) (Intent-to-Treat Population)

Incidence of all-cause death, non-fatal stroke, or need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: All-cause death: Death from any cause, Non-fatal Stoke: occurrence of a stoke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28

,
InterventionPercentage of Participants (Number)
Composite of All EventsAll-Cause DeathNon-Fatal StrokeNeed for Mechanical Support for SLVD
Acadesine4.91.91.72.2
Placebo4.91.71.72.3

Incidence of Cardiovascular Death, Non-fatal Stroke, and Need for Mechanical Support for SLVD (Intent-to-Treat Population)

Incidence of cardiovascular death, non-fatal stroke, and need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: Cardiovascular death: Death due to cardiovascular causes, Non-fatal Stroke: occurrence of a stroke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28

,
InterventionPercentage of Participants (Number)
Composite of All EventsCardiovascular DeathNon-Fatal StrokeNeed for Mechanical Support for SLVD
Acadesine4.81.71.72.2
Placebo (Normal Saline)4.71.61.72.3

Reviews

12 reviews available for aspirin and Left Ventricular Dysfunction

ArticleYear
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review.
    Rheumatology (Oxford, England), 2021, 10-02, Volume: 60, Issue:10

    Topics: Adolescent; Aspirin; C-Reactive Protein; Case-Control Studies; Child; Child, Preschool; Coronary Dis

2021
Thrombosis and embolism in pediatric cardiomyopathy.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:3

    Topics: Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Cardiomyopathy, Restrictive; Child; Disease Manage

2013
Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:2

    Topics: Anticoagulants; Aspirin; Heart Failure; Humans; Platelet Aggregation Inhibitors; Thromboembolism; Ve

2014
[Decreasing incidence of stent thrombosis].
    Annales de cardiologie et d'angeiologie, 2011, Volume: 60, Issue:6

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap

2011
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
    Lancet (London, England), 2002, Oct-05, Volume: 360, Issue:9339

    Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Drug

2002
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
    Circulation, 2004, Oct-19, Volume: 110, Issue:16

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie

2004
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
    Current opinion in cardiology, 1996, Volume: 11, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin;

1996
Contemporary issues in heart failure.
    American heart journal, 1999, Volume: 138, Issue:1 Pt 1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Anticoagulants; Aspirin; Communi

1999
How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI.
    American heart journal, 1999, Volume: 138, Issue:2 Pt 2

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Follow-Up Studies; H

1999
Anticoagulation and heart failure.
    Current cardiology reports, 2001, Volume: 3, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Heart Failure; Humans; Platelet A

2001
Should patients with hypertension receive antithrombotic therapy?
    Journal of internal medicine, 2001, Volume: 249, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hypertension; Myocardial Infarction; Risk Factors

2001
Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.
    Current cardiology reports, 2002, Volume: 4, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase

2002

Trials

12 trials available for aspirin and Left Ventricular Dysfunction

ArticleYear
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2021, 12-01, Volume: 78, Issue:12

    Topics: Adult; Aged; Aspirin; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Humans; Mal

2021
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.
    Journal of hypertension, 2013, Volume: 31, Issue:6

    Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Captopril; Europe; Female; Humans; Hypertens

2013
Predictors of contemporary coronary artery bypass grafting outcomes.
    The Journal of thoracic and cardiovascular surgery, 2014, Volume: 148, Issue:6

    Topics: Age Factors; Aminoimidazole Carboxamide; Aspirin; Cardiopulmonary Bypass; Cardiovascular Agents; Chi

2014
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid

2015
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.
    The American journal of cardiology, 2015, Sep-15, Volume: 116, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Platele

2015
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
    Journal of thrombosis and thrombolysis, 2010, Volume: 30, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies

2010
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud
    Clinical cardiology, 2012, Volume: 35, Issue:7

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Double-

2012
[Use of trimetazidine in the combined therapy of myocardial infarction with left ventricular dysfunction].
    Kardiologiia, 2002, Volume: 42, Issue:10

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Diur

2002
Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enzyme-Linked Immunosorbent Assay; Female; Heart

2005
Protecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgery.
    Seminars in cardiothoracic and vascular anesthesia, 2006, Volume: 10, Issue:1

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitor

2006
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
    Polskie Archiwum Medycyny Wewnetrznej, 1996, Volume: 95, Issue:1

    Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male

1996
Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction.
    Journal of cardiovascular pharmacology, 1999, Volume: 34, Issue:3

    Topics: Acetylcholine; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bradykinin; Coronary Angiog

1999

Other Studies

46 other studies available for aspirin and Left Ventricular Dysfunction

ArticleYear
Ventricular longitudinal shortening is an independent predictor of death in heart failure patients with reduced ejection fraction.
    Scientific reports, 2021, 10-13, Volume: 11, Issue:1

    Topics: Aged; Aspirin; Body Mass Index; Cicatrix; Diuretics; Female; Fibrosis; Follow-Up Studies; Heart Fail

2021
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:11

    Topics: Adult; Arrhythmias, Cardiac; Aspirin; Cardiomyopathies; Female; Heart Failure; Humans; Incidence; Ma

2019
Multisystem inflammatory syndrome in an adult with involvement of the skin, lymph nodes, muscle, heart, liver and kidneys.
    Rheumatology (Oxford, England), 2021, 11-03, Volume: 60, Issue:11

    Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Aspirin; Asymptomatic Infections; Biomarkers;

2021
Thrombolysis of prosthetic mitral valve thrombosis in an infant.
    Journal of cardiac surgery, 2017, Volume: 32, Issue:5

    Topics: Aspirin; Coronary Vessels; Female; Fibrinolytic Agents; Heart Septal Defects, Ventricular; Heart Val

2017
Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report.
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2019, Volume: 24, Issue:2

    Topics: Adrenergic beta-Antagonists; Angina, Stable; Aspirin; Bundle-Branch Block; Cardiotonic Agents; Compu

2019
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
    Acute cardiac care, 2013, Volume: 15, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiogra

2013
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
    Medicina clinica, 2014, Apr-07, Volume: 142, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; F

2014
Loading conditions influence reliability of the echocardiographic ramp test in continuous-flow left ventricular assist devices.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2013, Volume: 32, Issue:11

    Topics: Aged; Aspirin; Drug Therapy, Combination; Echocardiography; Eptifibatide; Heart-Assist Devices; Hemo

2013
Takotsubo cardiomyopathy after an emotional outburst.
    The Ceylon medical journal, 2015, Volume: 60, Issue:3

    Topics: Antihypertensive Agents; Aspirin; Carbazoles; Carvedilol; Diuretics; Echocardiography; Family Confli

2015
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:2

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Diabeti

2016
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.
    Journal of cardiovascular pharmacology, 2017, Volume: 69, Issue:5

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Clinica

2017
Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device.
    Texas Heart Institute journal, 2008, Volume: 35, Issue:3

    Topics: Adult; Aged; Aspirin; Brain Diseases, Metabolic; Cardiomyopathy, Dilated; Cause of Death; Cognition

2008
Off-pump replacement of the INCOR implantable axial-flow pump.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2009, Volume: 28, Issue:2

    Topics: Anticoagulants; Aspirin; Clopidogrel; Equipment Design; Heart-Assist Devices; Humans; Infusion Pumps

2009
Myocardial bridging with a coronary artery aneurysm and left ventricular stunning.
    The American journal of the medical sciences, 2011, Volume: 341, Issue:6

    Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Aneurysm; Exercise Test; Exercise Tolerance; Fibrinol

2011
An assessment of the concentration-related prognostic value of cardiac troponin I following acute coronary syndrome.
    The American journal of cardiology, 2011, Nov-01, Volume: 108, Issue:9

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; A

2011
Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure.
    Clinical hemorheology and microcirculation, 2011, Volume: 49, Issue:1-4

    Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Contrast Media; Coronary Angiography; Coronary Stenos

2011
Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2

    Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug The

2012
Cross-sectional study of treatment strategies on atrial fibrillation.
    Arquivos brasileiros de cardiologia, 2012, Volume: 98, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrilla

2012
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2012, Volume: 61, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Biom

2012
Multiple left ventricular thrombi in a patient with left ventricular noncompaction.
    Texas Heart Institute journal, 2012, Volume: 39, Issue:4

    Topics: Anticoagulants; Aspirin; Echocardiography, Doppler, Color; Echocardiography, Transesophageal; Female

2012
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:6

    Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Thrombosis; Europe; Fibrinolytic Agents; Hea

2012
Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study).
    European journal of heart failure, 2002, Volume: 4, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor

2002
Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.
    Clinical cardiology, 2004, Volume: 27, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography; Female; Fibrinoly

2004
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
    The American journal of cardiology, 2004, Jun-15, Volume: 93, Issue:12

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti

2004
Late incidence and determinants of stroke after aortic and mitral valve replacement.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral

2004
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
    Age and ageing, 2004, Volume: 33, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Fibrill

2004
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
    Journal of the American College of Cardiology, 2004, Oct-19, Volume: 44, Issue:8

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi

2004
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
    Acta cardiologica, 2005, Volume: 60, Issue:1

    Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy

2005
Impact of the National Service Framework for coronary heart disease on treatment and outcome of patients with acute coronary syndromes.
    Heart (British Cardiac Society), 2006, Volume: 92, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiac Catheterizat

2006
Medication performance measures and mortality following acute coronary syndromes.
    The American journal of medicine, 2005, Volume: 118, Issue:8

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhi

2005
Takotsubo cardiomyopathy.
    Internal medicine journal, 2007, Volume: 37, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathi

2007
[The "tako-tsubo" syndrome: report of two cases].
    Annales de cardiologie et d'angeiologie, 2007, Volume: 56, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiomyopathies; Electrocardiography; Female; Humans; H

2007
Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cyclooxygenase 1; Cycloox

2007
Concentration and quality of hospitals that care for elderly black patients.
    Archives of internal medicine, 2007, Jun-11, Volume: 167, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents;

2007
[What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?].
    Annales de cardiologie et d'angeiologie, 1994, Volume: 43, Issue:9

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Vessels; Hu

1994
Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats.
    Cardiovascular research, 1998, Volume: 37, Issue:1

    Topics: Adrenergic beta-Agonists; Animals; Aspirin; Drug Administration Schedule; Heart Rate; Hemodynamics;

1998
Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
    Journal of the American College of Cardiology, 1998, Volume: 32, Issue:2

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary

1998
ACE inhibitors in acute myocardial infarction.
    Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T

1998
Evaluating quality of care for patients with heart failure.
    Circulation, 2000, Mar-28, Volume: 101, Issue:12

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin

2000
Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction.
    The American journal of cardiology, 2000, Apr-15, Volume: 85, Issue:8

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Incidence; Intracranial Embolism

2000
Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts.
    Cardiovascular research, 2000, Volume: 46, Issue:2

    Topics: Adrenergic beta-Agonists; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal

2000
[Acute myocardial infarction: management, prognosis and survival].
    Revue medicale de Liege, 2000, Volume: 55, Issue:4

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non

2000
Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy.
    European journal of heart failure, 1999, Volume: 1, Issue:3

    Topics: Aged; Aspirin; Biomarkers; Cardiomyopathy, Dilated; Coronary Disease; Enzyme-Linked Immunosorbent As

1999
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
    The American journal of medicine, 2000, Oct-01, Volume: 109, Issue:5

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors

2000
Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure.
    The American journal of cardiology, 2001, Feb-15, Volume: 87, Issue:4

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chi-Square Distribution; Cohort Studies; Cy

2001
Care of acute myocardial infarction in Oklahoma: an update from the Cooperative Cardiovascular Project.
    The Journal of the Oklahoma State Medical Association, 2001, Volume: 94, Issue:10

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc

2001